Posts Tagged ‘obesity’

In the midst of a lot of blather that assigns magical medical properties to food, its downright refreshing to read reflections from Tamar Haspel on the nature of food in Italy – and how people enjoy their food in that country. It is the food environment in Italy, not the food itself, that seems to […]

We do admire folks who are willing to go out on a limb and put work into a subject as tough as the tensions between care for eating disorders and obesity. In a thoughtful new book, Marian Tanofsky-Kraff, Natasha Schvey, Robyn Pashby, and Natasha Burke are turning the page on an unhelpful “food fight.” Though […]

A new report from Reuters tells us that Novo Nordisk is having a hard time coming to terms with its failure to solidify a leadership position in the obesity market it created from nothing with semaglutide. Former executives and financial analysts alike say the company was too conservative and unprepared for a blockbuster launch: “way, way, […]

People living with obesity face a heavy and often hidden burden – financial, physical, social, and psychological – embedded in health systems and extending far beyond health risks. A nationally representative U.S. study reveals that one in six adults with obesity struggles to afford healthcare, routinely skipping medications or even meals to manage cost. With […]

Stepping back from the intense swirl of obesity care research at the ADA meeting just concluded, one thing stands out: People are having a very hard time following the thread of all this innovation. If you have any doubt, just scan the reports of investment analysts at the meeting. On one hand, they know they […]

For the last 18 months, some of the smartest people we know in the realm of obesity policy have been busy drawing a map. Their map, announced today, shows the way for transforming obesity care through three solution areas. These include creating engagement, building capabilities, and delivering integrated care. It comes from the Center for […]

With two new publications in the New England Journal of Medicine, we are thinking that CagriSema has something to teach us about using weight loss outcomes to judge the merits of a new obesity medicine. Is more always better? Researchers presented the data from these two pivotal clinical trials on CagriSema at the ADA Scientific […]

We are only halfway through ADA2025 in Chicago and already the flood of information about new drugs for obesity like orforglipron, amycretin, and a host of others leaves us feeling like we have been sprayed down by a fire hose. Much more will be coming at us in the next two days. Orforglipron and Other […]

“It takes a village to create standards of care,” said Nuha Ali El Sayed as she opened a symposium on the emerging standards of care for obesity. Truer words were never spoken. Defining these standards is tricky. That’s because they they need to reflect both what is desirable and a standard that good health professionals […]

In drug therapy for obesity, all of the excitement about GLP-1s and now amylin analogs has focused on regulation of eating behaviors. But, in fact, this is just one part of the process for regulating metabolic function and adiposity. Until now, we have seen little success in developing safe and effective medicines that alter the […]